Clinical trial NCT05455320: A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
Official title: A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 1 Prior Line of Therapy
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Relapsed or Refractory Multiple Myeloma
Lead sponsor: Janssen Research & Development, LLC
Sponsor class: INDUSTRY
First posted: 2022-07-13
Enrollment: 810
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd).


Eligibility criteria: Inclusion Criteria:

* Documented multiple myeloma as defined: a) Multiple myeloma diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria and b) Measurable disease at screening as defined by any of the following: i) Serum M-protein level greater than or equal to (\>=) 0.5 grams per deciliter (g/dL) (central laboratory); ii) Urine M-protein level \>= 200 milligram (mg) per 24 hours (central laboratory); iii) Light chain multiple myeloma without measurable M-protein in the serum or the urine: serum immunoglobulin free light chain \>= 10 milligram per deciliter (mg/dL) (central laboratory), and abnormal serum immunoglobulin kappa lambda free light chain ratio
* Relapsed or refractory disease as defined by: i) Relapsed disease is defined as an initial response to prior treatment, followed by confirmed progressive disease by IMWG criteria greater than (\>) 60 days after cessation of treatment; ii) Refractory disease is defined as less than (\<) 25 percent (%) reduction in monoclonal paraprotein (M-protein) or confirmed progressive disease by IMWG criteria during previous treatment or less than or equal to (\<=) 60 days after cessation of treatment
* Received at least 1 prior line of antimyeloma therapy including a proteasome inhibitor (PI) and lenalidomide. Participants who have received only 1 prior line of antimyeloma therapy must be considered lenalidomide-refractory (that is, have demonstrated progressive disease by IMWG criteria on or within 60 days of completion of lenalidomide-containing regimen). Participants who have received \>=2 prior lines of antimyeloma therapy must be considered lenalidomide exposed
* Documented evidence of progressive disease based on investigator's determination of response by the IMWG criteria on or after their last regimen
* Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 at screening and immediately prior to the start of administration of study treatment

Exclusion Criteria:

* Contraindications or life-threatening allergies, hypersensitivity, or intolerance to study drug excipients
* Disease is considered refractory to an anti-cluster of differentiation 38 (CD38) monoclonal antibody as defined per IMWG consensus guidelines (progression during treatment or within 60 days of completing therapy with an anti-CD38 monoclonal antibody)
* Received prior pomalidomide therapy
* A maximum cumulative dose of corticosteroids to \>=140 milligrams (mg) of prednisone or equivalent within 14-day period before the first dose of study drug
* Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required
* Plasma cell leukemia (per IMWG criteria) at the time of screening, Waldenström's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS syndrome), or primary amyloid light chain amyloidosis

Primary outcomes:
measure: Progression-Free Survival (PFS)
timeFrame: Up to 6 years 6 months
Secondary outcomes:
measure: Overall Response (Partial Response [PR] or Better)
timeFrame: Up to 6 years 6 months
measure: Very Good Partial Response (VGPR) or Better Rate
timeFrame: Up to 6 years 6 months
measure: Complete Response (CR) or Better Rate
timeFrame: Up to 6 years 6 months
measure: Overall Minimal Residual Disease (MRD) Negative CR
timeFrame: Up to 6 years 6 months
measure: Overall Survival (OS)
timeFrame: Up to 6 years 6 months
measure: Progression-free Survival on Next-line Therapy (PFS2)
timeFrame: Up to 6 years 6 months
measure: Time to Next Therapy (TTNT)
timeFrame: Up to 6 years 6 months
measure: Number of Participants with Adverse Events (AEs)
timeFrame: Up to 6 years 6 months
measure: Number of Participants with AEs by Severity
timeFrame: Up to 6 years 6 months
measure: Serum Concentrations of Talquetamab
timeFrame: Up to 6 years 6 months
measure: Serum Concentrations of Daratumumab
timeFrame: Up to 6 years 6 months
measure: Number of Participants with Presence of Anti-Drug Antibodies (ADAs) to Talquetamab
timeFrame: Up to 6 years 6 months
measure: Number of Participants With Presence of Anti-Drug Antibodies (ADAs) to Daratumumab
timeFrame: Up to 6 years 6 months
measure: Time to Worsening in Symptoms, Functioning, and Overall Health-Related Quality of Life (HRQoL) as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q)
timeFrame: Up to 6 years 6 months
measure: Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by PROMIS Short Form Version 2.0 -Physical Functioning 8c
timeFrame: Up to 6 years 6 months
measure: Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by EORTC-QLQ-C30
timeFrame: Up to 6 years 6 months
measure: Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by PRO-CTCAE
timeFrame: Up to 6 years 6 months
measure: Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L)
timeFrame: Up to 6 years 6 months
measure: Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by Patient Global Impression - Severity (PGI-S)
timeFrame: Up to 6 years 6 months
measure: Change From Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q)
timeFrame: Baseline up to 6 years 6 months
measure: Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by PROMIS Short Form Version 2.0 -Physical Functioning 8c
timeFrame: Baseline up to 6 years 6 months
measure: Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by EORTC-QLQ-C30
timeFrame: Baseline up to 6 years 6 months
measure: Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by PRO-CTCAE
timeFrame: Baseline up to 6 years 6 months
measure: Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L)
timeFrame: Baseline up to 6 years 6 months
measure: Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by Patient Global Impression - Severity (PGI-S)
timeFrame: Baseline up to 6 years 6 months
Other outcomes:
Locations:
city: Tucson
country: United States
facility: The University of Arizona Cancer Center
state: Arizona
city: Little Rock
country: United States
facility: University of Arkansas for Medical Sciences
state: Arkansas
city: Norwalk
country: United States
facility: Norwalk Hospital-oncology
state: Connecticut
city: Washington
country: United States
facility: MedStar Georgetown University Hospital
state: District of Columbia
city: Washington
country: United States
facility: George Washington University
state: District of Columbia
city: Hollywood
country: United States
facility: Memorial Healthcare System
state: Florida
city: Miami
country: United States
facility: University of Miami Health System
state: Florida
city: Chicago
country: United States
facility: University Of Illinois
state: Illinois
city: Westwood
country: United States
facility: University of Kansas
state: Kansas
city: New Orleans
country: United States
facility: Tulane University Hospital & Clinics
state: Louisiana
city: New Orleans
country: United States
facility: Ochsner Health System
state: Louisiana
city: Baltimore
country: United States
facility: Johns Hopkins University
state: Maryland
city: Boston
country: United States
facility: Massachusetts General
state: Massachusetts
city: Boston
country: United States
facility: Boston University Medical Center
state: Massachusetts
city: Worcester
country: United States
facility: University of Massachusetts Medical School
state: Massachusetts
city: Ann Arbor
country: United States
facility: University of Michigan Health System
state: Michigan
city: Minneapolis
country: United States
facility: University Of Minnesota
state: Minnesota
city: Jackson
country: United States
facility: University of Mississippi Medical Center
state: Mississippi
city: Saint Louis
country: United States
facility: Washington University School Of Medicine
state: Missouri
city: New Brunswick
country: United States
facility: Rutgers Cancer Institute of New Jersey
state: New Jersey
city: New York
country: United States
facility: NYU Langone Health
state: New York
city: Syracuse
country: United States
facility: SUNY Upstate Medical University
state: New York
city: Chapel Hill
country: United States
facility: University of North Carolina
state: North Carolina
city: Charlotte
country: United States
facility: Levine Cancer Institute, Carolinas HealthCare System
state: North Carolina
city: Charlotte
country: United States
facility: Novant Health
state: North Carolina
city: Winston-Salem
country: United States
facility: Novant Health
state: North Carolina
city: Winston-Salem
country: United States
facility: Wake Forest Baptist Medical Center
state: North Carolina
city: Cleveland
country: United States
facility: University Hospitals Cleveland Medical Center
state: Ohio
city: Columbus
country: United States
facility: The Ohio State University Wexner Medical Center - James Cancer Hospital
state: Ohio
city: Columbus
country: United States
facility: OhioHealth
state: Ohio
city: Philadelphia
country: United States
facility: Thomas Jefferson University
state: Pennsylvania
city: Charleston
country: United States
facility: Medical University of South Carolina
state: South Carolina
city: Memphis
country: United States
facility: Baptist Cancer Center
state: Tennessee
city: Houston
country: United States
facility: Houston Methodist Hospital
state: Texas
city: Houston
country: United States
facility: MD Anderson Cancer Center
state: Texas
city: Lubbock
country: United States
facility: Joe Arrington Cancer Research Treatment Center
state: Texas
city: Salt Lake City
country: United States
facility: Huntsman Cancer Institute
state: Utah
city: Charlottesville
country: United States
facility: University of Virginia
state: Virginia
city: Richmond
country: United States
facility: Virginia Commonwealth University - Massey Cancer Center
state: Virginia
city: Seattle
country: United States
facility: Fred Hutchinson Cancer Research Center
state: Washington
city: Brussel
country: Belgium
facility: UZ Brussel
city: Edegem
country: Belgium
facility: UZA
city: Hasselt
country: Belgium
facility: Virga Jessa Ziekenhuis
city: Liège
country: Belgium
facility: CHC MontLegia
city: Ottignies
country: Belgium
facility: Clinique Saint Pierre
city: Yvoir
country: Belgium
facility: UCL Mont Godinne
city: Barretos
country: Brazil
facility: Fundacao Pio XII
city: Belo Horizonte
country: Brazil
facility: Santa Casa de Misericordia de Belo Horizonte
city: Brasilia
country: Brazil
facility: Hospitais Integradaos da Gavea S/A - DF Star
city: Caxias do Sul
country: Brazil
facility: Fundacao Universidade de Caxias do Sul
city: Curitiba
country: Brazil
facility: Liga Paranaense de Combate ao Cancer
city: Florianopolis
country: Brazil
facility: Centro de Pesquisa e Ensino em Oncologia de Santa Catarina CEPEN
city: Natal
country: Brazil
facility: Liga Norte Riograndense Contra O Cancer
city: Porto Alegre
country: Brazil
facility: Irmandade Santa Casa de Misericordia de Porto Alegre
city: Ribeirao Preto
country: Brazil
facility: Hospital Das Clinicas Da Faculdade De Medicina De RPUSP HCRP
city: Rio de Janeiro
country: Brazil
facility: Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)
city: Salvador
country: Brazil
facility: Hospital Sao Rafael
city: Sao Paulo
country: Brazil
facility: Hospital Paulistano
city: Sao Paulo
country: Brazil
facility: Instituto D Or de Pesquisa e Ensino IDOR
city: Sao Paulo
country: Brazil
facility: Fundacao Antonio Prudente A C Camargo Cancer Center
city: São Paulo
country: Brazil
facility: Sociedade Beneficente de Senhoras Hospital Sirio Libanes
city: São Paulo
country: Brazil
facility: Real e Benemerita Associacao Portuguesa de Beneficencia
city: São Paulo
country: Brazil
facility: Clinica Sao Germano
city: Beijing
country: China
facility: Peking Union Medical College Hospital
city: Beijing
country: China
facility: Beijing Chaoyang Hospital
city: Beijing
country: China
facility: Peking University First Hospital
city: Changchun
country: China
facility: The First Hospital of Jilin University
city: ChangSha
country: China
facility: The second Xiangya Hospital of Central South University
city: Chengdu
country: China
facility: Sichuan Academy of Medical Science Sichuan Provincial People's Hospital
city: Fuzhou
country: China
facility: Fujian Medical University Union Hospital
city: Guang Zhou Shi
country: China
facility: Sun Yat Sen University Cancer Center
city: Guangzhou
country: China
facility: Guangdong Provincial People's Hospital
city: Hangzhou
country: China
facility: The First Affiliated Hospital Zhejiang University College of Medicine
city: Nanjing
country: China
facility: Nanjing Drum Tower Hospital
city: Shanghai
country: China
facility: Tongji Hospital of Tongji University
city: Shanghai
country: China
facility: Shanghai Fourth People s Hospital
city: Shenzhen
country: China
facility: Peking University Shenzhen Hospital
city: Su Zhou
country: China
facility: First Affiliated Hospital SooChow University
city: Tianjin
country: China
facility: Tianjin cancer hospital
city: Tianjin
country: China
facility: Institute of Hematology & Blood Disease Hospital Chinese Academy of Medical Science
city: Wuhan
country: China
facility: Tongji Hospital, Tongji Medical College of HUST
city: Zhengzhou
country: China
facility: Henan Cancer Hospital
city: Brno
country: Czechia
facility: Fakultni nemocnice Brno
city: Hradec Kralove
country: Czechia
facility: Fakultni nemocnice Hradec Kralove
city: Olomouc
country: Czechia
facility: Fakultni nemocnice Olomouc
city: Ostrava - Poruba
country: Czechia
facility: Fakultni Nemocnice Ostrava
city: Praha 10
country: Czechia
facility: Fakultni nemocnice Kralovske Vinohrady
city: Praha 2
country: Czechia
facility: Vseobecna fakultni nemocnice v Praze - I. interni klinika - klinika hematologie
city: Creteil
country: France
facility: APHP - Hopital Henri Mondor
city: Dijon
country: France
facility: CHU Dijon
city: Lyon
country: France
facility: Centre Leon Berard
city: Montpellier Cedex 5
country: France
facility: CHU de Montpellier - Hopital Saint-Eloi
city: Nantes
country: France
facility: CHU de Nantes hotel Dieu
city: Nice N/a
country: France
facility: CHU HOPITAL DE L'ARCHET - Hematology
city: Paris Cedex 12
country: France
facility: CHU Hopital Saint Antoine
city: Pessac
country: France
facility: CHRU - Hôpital du Haut Lévêque - Centre François Magendie
city: TOULOUSE Cedex 9
country: France
facility: Institut Universitaire du cancer de Toulouse-Oncopole
city: Berlin
country: Germany
facility: Charite Campus Benjamin Franklin
city: Hamburg
country: Germany
facility: Asklepios Klinik Altona
city: Heidelberg
country: Germany
facility: Universitaetsklinikum Heidelberg
city: Koeln
country: Germany
facility: Universitaetsklinikum Koelnt
city: Leipzig
country: Germany
facility: Universitaetsklinikum Leipzig
city: Mainz
country: Germany
facility: Universitätsmedizin der Johannes Gutenberg Universität
city: Wuerzburg
country: Germany
facility: Universitaetsklinikum Wuerzburg
city: Athens Attica
country: Greece
facility: Alexandra General Hospital of Athens
city: Thessalonikis
country: Greece
facility: G Papanikolaou Hospital of Thessaloniki
city: Thessaloniki
country: Greece
facility: Anticancer Hospital of Thessaloniki Theageneio
city: Afula
country: Israel
facility: Ha'Emek Medical Center
city: Be Er Ya Akov
country: Israel
facility: Shamir Medical Center Assaf Harofeh
city: Hadera
country: Israel
facility: Hillel Yaffe Medical Center
city: Haifa
country: Israel
facility: Bnai Zion Medical Center
city: Haifa
country: Israel
facility: Rambam Medical Center
city: Haifa
country: Israel
facility: Carmel Medical Center
city: Jerusalem
country: Israel
facility: Shaare Zedek Medical Center
city: Nahariya
country: Israel
facility: Galilee Medical Center
city: Petah Tikva
country: Israel
facility: Beilinson medical center
city: Ramat Gan
country: Israel
facility: Sheba Medical Center
city: Safed
country: Israel
facility: Ziv Medical Center
city: Tel Aviv
country: Israel
facility: Sourasky (Ichilov) Medical Center
city: Ancona
country: Italy
facility: A.O. Universitaria Ospedali Riuniti di Ancona
city: Bari
country: Italy
facility: Policlinico di Bari
city: Bologna
country: Italy
facility: Azienda Ospedaliera Policlinico S. Orsola-Malpighi
city: Brescia
country: Italy
facility: Azienda Ospedaliera Spedali Civili di Brescia
city: Catania
country: Italy
facility: PO G.Rodolico, AOU Policlinico-Vittorio Emanuele Catania
city: Milano
country: Italy
facility: Fondazione IRCCS Istituto Nazionale dei Tumori
city: Milano
country: Italy
facility: ASST Grande Ospedale Metropolitano Niguarda
city: Padova
country: Italy
facility: Azienda Ospedaliera Universitaria di Padova
city: Palermo
country: Italy
facility: Ospedale Villa Sofia-Cervello
city: Pavia
country: Italy
facility: Fondazione IRCCS Policlinico San Matteo
city: Reggio Emilia
country: Italy
facility: Arcispedale Santa Maria Nuova - IRCCS
city: Roma
country: Italy
facility: Presidio Ospedaliero Santo Spirito in Sassia
city: San Giovanni Rotondo
country: Italy
facility: IRCCS Ospedale Casa Sollievo della Sofferenza
city: Torino
country: Italy
facility: A.O.U. Città della Salute e della Scienza
city: Bunkyo ku
country: Japan
facility: Institute of Science Tokyo Hospital
city: Chiba
country: Japan
facility: Chiba Cancer Center
city: Fukuoka
country: Japan
facility: Fukuoka University Hospital
city: Gifu
country: Japan
facility: Ogaki Municipal Hospital
city: Gunma
country: Japan
facility: Gunma University Hospital
city: Hirakata
country: Japan
facility: Kansai Medical University Hospital
city: Hyogo
country: Japan
facility: Japanese Red Cross Society Himeji Hospital
city: Hyôgo
country: Japan
facility: Hyogo Medical University Hospital
city: Kamakura-shi
country: Japan
facility: Shonan Kamakura General Hospital
city: Kashiwa
country: Japan
facility: National Cancer Center Hospital East
city: Koshigaya
country: Japan
facility: Dokkyo Medical University Saitama Medical Center
city: Kumamoto
country: Japan
facility: Kumamoto University Hospital
city: Kyoto
country: Japan
facility: Kyoto Kuramaguchi Medical Center
city: Matsumoto
country: Japan
facility: National Hospital Organization Matsumoto Medical Center
city: Niigata
country: Japan
facility: Niigata Cancer Center Hospital
city: Otake
country: Japan
facility: National Hospital Organization Hiroshima-Nishi Medical Center
city: Sapporo-shi
country: Japan
facility: Hokkaido University Hospital
city: Sendai
country: Japan
facility: Tohoku University Hospital
city: Shiwa-gun
country: Japan
facility: Iwate Medical University Hospital
city: Suita City
country: Japan
facility: The University of Osaka Hospital
city: Tokyo
country: Japan
facility: The Cancer Institute Hospital of JFCR
city: Busan
country: Korea, Republic of
facility: Dong-A University Hospital
city: Gyeonggi-do
country: Korea, Republic of
facility: National Cancer Center
city: Incheon
country: Korea, Republic of
facility: Gachon University Gil Medical Center
city: Jeollanam-do
country: Korea, Republic of
facility: Chonnam National University Hwasun Hospital
city: Jeonju-si
country: Korea, Republic of
facility: Jeonbuk National University Hospital
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
city: Seoul
country: Korea, Republic of
facility: Severance Hospital Yonsei University Health System
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
city: Seoul
country: Korea, Republic of
facility: The Catholic University of Korea Seoul St Marys Hospital
city: Dordrecht
country: Netherlands
facility: Albert Schweitzer ziekenhuis-lokatie Dordwijk
city: Eindhoven
country: Netherlands
facility: Maxima Medisch Centrum
city: Rotterdam
country: Netherlands
facility: Erasmus MC
city: Brzozow
country: Poland
facility: Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im Ks B Markiewicza
city: Gdansk
country: Poland
facility: Uniwersyteckie Centrum Kliniczne
city: Katowice
country: Poland
facility: Pratia Onkologia Katowice
city: Kielce
country: Poland
facility: Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach
city: Krakow
country: Poland
facility: Szpital Uniwersytecki w Krakowie
city: Lublin
country: Poland
facility: Centrum Onkologii Ziemi Lubelskiej im sw Jana z Dukli
city: Olsztyn
country: Poland
facility: Szpital Kliniczny MSWiA z Warminsko Mazurskim Centrum Onkologii w Olsztynie Oddzial Hematologii
city: Szczecin
country: Poland
facility: Uniwersytecki Szpital Kliniczny Nr 1 PUM im prof Tadeusza Sokolowskiego w Szczecinie
city: Torun
country: Poland
facility: Wojewodzki Szpital Zespolony im L Rydygiera w Toruniu
city: Warszawa
country: Poland
facility: Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
city: Wroclaw
country: Poland
facility: Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu
city: Badalona
country: Spain
facility: Hosp. Univ. Germans Trias I Pujol
city: Barcelona
country: Spain
facility: Hosp. de La Santa Creu I Sant Pau
city: Barcelona
country: Spain
facility: Hosp Univ Vall D Hebron
city: Barcelona
country: Spain
facility: Hosp Clinic de Barcelona
city: El Palmar
country: Spain
facility: Hosp. Univ. Virgen de La Arrixaca
city: Jerez de la Frontera
country: Spain
facility: Hosp. de Jerez de La Frontera
city: Leon
country: Spain
facility: Hosp. de Leon
city: Madrid
country: Spain
facility: Hosp. Univ. de La Princesa
city: Madrid
country: Spain
facility: Hosp. Univ. Ramon Y Cajal
city: Madrid
country: Spain
facility: Hosp. Univ. 12 de Octubre
city: Madrid
country: Spain
facility: Hosp Univ Hm Sanchinarro
city: Malaga
country: Spain
facility: Hosp Virgen de La Victoria
city: Pamplona
country: Spain
facility: Clinica Univ. de Navarra
city: Salamanca
country: Spain
facility: Hosp Clinico Univ de Salamanca
city: San Cristóbal de La Laguna
country: Spain
facility: Hosp. Univ. de Canarias
city: Valencia
country: Spain
facility: Hosp. Univ. Dr. Peset
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Medical University Chung Ho Memorial Hospital
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Chang Gung Memorial Hospital
city: Taichung City
country: Taiwan
facility: China Medical University Hospital
city: Tainan
country: Taiwan
facility: National Cheng Kung University Hospital
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
city: Ankara
country: Turkey
facility: Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Hematology Unit
city: Ankara
country: Turkey
facility: Ankara University Medical Faculty
city: Ankara
country: Turkey
facility: Liv Hospital Ankara
city: Antalya
country: Turkey
facility: Antalya Training And Research Hospital
city: Istabul
country: Turkey
facility: Medipol Mega University Hospital
city: Istanbul
country: Turkey
facility: Istanbul University Istanbul Medical Faculty
city: Istanbul
country: Turkey
facility: Istanbul University Cerrahpasa Medical Faculty
city: Izmir
country: Turkey
facility: Dokuz Eylul University Medical Faculty
city: Samsun
country: Turkey
facility: Ondokuz Mayis University
city: Blackpool
country: United Kingdom
facility: Blackpool Victoria Hospital
city: Dundee
country: United Kingdom
facility: Ninewells Hospital & Medical School
city: London
country: United Kingdom
facility: Hammersmith Hospital
city: Newcastle Upon Tyne
country: United Kingdom
facility: Newcastle Freeman Hospital
city: Nottingham
country: United Kingdom
facility: Nottingham City Hospital
city: Plymouth
country: United Kingdom
facility: University Hospitals Plymouth NHS Trust
city: Sutton
country: United Kingdom
facility: Royal Marsden Hospital
city: Wolverhampton
country: United Kingdom
facility: New Cross Hospital
Study officials:
affiliation: Janssen Research & Development, LLC
name: Janssen Research & Development, LLC Clinical Trial
role: STUDY_DIRECTOR
References: